Company news

Kyverna Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024

November 13, 2024

Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

November 12, 2024

Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors

October 20, 2024

Kyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory Diseases in Symposium at ECTRIMS 2024

September 17, 2024

Kyverna Therapeutics Announces Leadership Update

September 15, 2024

Kyverna Therapeutics to Participate in Upcoming September Investor Conferences

August 20, 2024

Kyverna Therapeutics Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Progressive Myasthenia Gravis

August 11, 2024

Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

August 11, 2024

Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome

July 14, 2024

Kyverna's KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial

June 19, 2024

First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS)

June 16, 2024

Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology

June 9, 2024

Kyverna Therapeutics to Present Data on 50 Patient Experience at Symposium at EULAR 2024

June 6, 2024

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

May 13, 2024

Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases

April 10, 2024

First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med

March 28, 2024

Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results

March 25, 2024

Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis

March 6, 2024

Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

February 11, 2024

← Newer news releases

Decks

The 5 newest of 11 decks. Every deck is listed under its year.